Chang Nancy T. - 07 Apr 2026 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GRTX
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 16:37:48 UTC
Prior SEC filing: 11 Dec 2025
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Nancy T. Chang

Key filing fact

Chang Nancy T. filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 09 Apr 2026.

Key facts

This page summarizes Chang Nancy T.'s Form 4 filing for Galera Therapeutics, Inc. (GRTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Apr 2026, 16:37.

Change

Previous filing in this sequence was filed on 11 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001135041 Primary reporting owner

CHANG NANCY T

Relationship: Director, 10%+ Owner
Address: C/O GALERA THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 225, MALVERN
Signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Nancy T. Chang
Signature date: 09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GRTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,180,611
Change %: +15%
Price
Shares after: 8,825,543
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,181
Change %: -64%
Price: $0.000000^*
Shares after: 661
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,180,611
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.